Peptone Company Market Research Report

Company Overview

Name: Peptone Ltd.

Mission: To focus on the discovery of novel therapeutics against intrinsically disordered targets, utilizing cutting-edge biophysics and computational methodologies.

Foundation:

• Founded by: Dr. Kamil Tamiola

• Heritage: The company was born out of 30 years of combined academic research into Intrinsically Disordered Proteins at institutions such as Cambridge, Oxford, ETH Zurich, and the University of Groningen.

Key People:

• Dr. Kamil Tamiola: Chief Executive Officer and Founder

• Dr. Andrew Allen: Chairman of the Board

• Dr. George Golumbeski: Non-Executive Director

• Andrew Hedin: Venture Capital Investor

• Dr. Francis Ho: Venture Capital Investor

• Hussein Kanji: Venture Capital Investor

• Dr. Peter Kiener: Non-Executive Director

• Dr. Alex Pasteur: Venture Capital Investor

• Dr. Anastasiya Sybirna: Board Observer

Headquarters:

• Corporate HQ: London, UK

• Protein Biophysics Research Facility: Bellinzona, Switzerland

• Supercomputer Location: Verne Global’s data center in Keflavik, Iceland

Number of Employees: No information is available.

Revenue: No information is available.

Company Specialization: Peptone is known for its expertise in pre-clinical translational biophysics and its focus on the discovery of novel therapeutics targeting intrinsically disordered proteins. The company utilizes sophisticated techniques such as nuclear magnetic resonance (NMR) spectroscopy and hydrogen-exchange mass spectrometry (HDX-MS) to analyze protein dynamics.

Products

Offerings: Peptone focuses on the discovery and development of therapeutics against intrinsically disordered proteins. Specific products are not listed in the available information.

High-Level Description:
Peptone integrates physics, molecular biology, and supercomputing to devise and refine drug candidates for complex protein targets.

• Key Features:

• Use of next-generation supercomputing for physical modeling and simulations.

• Employment of advanced structural analysis techniques such as NMR spectroscopy and HDX-MS.

• Interactive cycles of prediction, laboratory testing, and refinement to generate viable drug candidates.

Recent Developments

• New Products Launched: No specific new product launches are available in the data.

• New Features: No specific new features added to existing products are mentioned in the provided data.

• Partnerships: No information about new partnerships is available.

Summary of Recent Activities:
Peptone is continuously evolving through its focus on cutting-edge research and supercomputing methods to refine potential drug candidates. The company leverages a sustainable infrastructure by employing 100% renewable energy for its supercomputer operations in Iceland. However, specific recent product developments or partnerships are not detailed in the currently available data.